Article
Oncology
Wing-Lok Chan, Cheuk-Wai Choi, Ian Yu-Hong Wong, Terence Hon-Ting Tsang, Adrian Tin-Chung Lam, Rosa Pui-Ying Tse, K. K. Chan, Claudia Wong, Betty Tze-Ting Law, Emina Edith Cheung, Siu-Yin Chan, Ka-On Lam, Dora Kwong, Simon Law
Summary: This study reviewed the long-term clinical outcomes and safety data of induction chemotherapy followed by surgery or definitive chemoradiotherapy in patients with locally advanced unresectable esophageal cancer. The results showed that patients who received subsequent surgery had significantly longer median overall survival compared to those who had definitive chemoradiotherapy or no definitive treatment. Induction chemotherapy followed by conversion surgery offered a chance of cure with long-term survival benefit and manageable toxicities in these patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Shiliang Liu, Liling Luo, Lei Zhao, Yujia Zhu, Hui Liu, Qiaoqiao Li, Ling Cai, Yonghong Hu, Bo Qiu, Li Zhang, Jingxian Shen, Yadi Yang, Mengzhong Liu, Mian Xi
Summary: "The results of this study show that the addition of induction chemotherapy to definitive chemoradiotherapy does not improve the response rate or survival of patients with unresectable esophageal squamous cell carcinoma."
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Hisanaga Nomura, Daiki Tsuji, Shohei Ueno, Takashi Kojima, Satoshi Fujii, Tomonori Yano, Hiroyuki Daiko, Ken Demachi, Kunihiko Itoh, Toshikatsu Kawasaki
Summary: The study aimed to investigate the association between clinical response to preoperative DCF therapy and genetic polymorphisms in esophageal cancer patients. Results revealed that XRCC3 rs1799794 is a genetic factor that affects the clinical response to DCF therapy.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Oncology
Stefano Kim, Jihane Boustani, Dewi Vernerey, Veronique Vendrely, Ludovic Evesque, Eric Francois, Laurent Quero, Francois Ghiringhelli, Christelle de la Fouchardiere, Laetitia Dahan, Oliver Bouche, Benoist Chibaudel, Farid El Hajbi, Chloe Vernet, Magali Rebucci-Peixoto, Alexandra Feuersinger, Christophe Maritaz, Christophe Borg
Summary: The INTERACT-ION study aims to assess the combination of mDCF with ezabenlimab in patients with Stage III SCAC, and investigate potential predictors of treatment response and resistance through extensive biomarker studies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
M. A. S. A. N. O. B. U. NAKAJIMA, H. I. R. O. T. O. MUROI, M. A. I. K. O. KIKUCHI, T. S. U. K. A. S. A. KUBO, S. H. U. H. E. I. TAKISE, K. E. I. S. U. K. E. IHARA, M. A. S. A. T. O. S. H. NAKAGAWA, S. H. I. N. J. I. MORITA, T. A. K. A. T. O. S. H. NAKAMURA, S. A. T. O. R. U. YAMAGUCHI, K. A. Z. U. Y. U. K. I. KOJIMA
Summary: This study analyzed the outcomes of DCF therapy and DCF-RT therapy in patients with cT4b esophageal cancer. The results showed that DCF-RT therapy tended to prolong survival and conversion surgery could improve therapeutic outcomes.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Takanori Yoshimoto, Tadayuki Oshima, Takashi Fukada, Nobuko Imamura, Takashi Nakanishi, Nobuhiko Ebisutani, Daisuke Morishita, Masatoshi Mieno, Keisuke Nakai, Hiroo Sei, Yoshitaka Kitayama, Hirotsugu Eda, Takuya Okugawa, Toshihiko Tomita, Hirokazu Fukui, Shinichiro Shinzaki
Summary: Early administration of pegfilgrastim is a safe and effective strategy to reduce the incidence of febrile neutropenia in DCF therapy. Using pegfilgrastim in conjunction with continuous 5-fluorouracil infusion in the DCF regimen is a reasonable option for preventing febrile neutropenia.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Takahito Sugase, Keijiro Sugimura, Takashi Kanemura, Tomohira Takeoka, Masaaki Yamamoto, Naoki Shinno, Hisashi Hara, Takeshi Omori, Yoshiaki Fujii, Yosuke Mukai, Manabu Mikamori, Shinichiro Hasegawa, Naotsugu Haraguchi, Hirofumi Akita, Junichi Nishimura, Hiroshi Wada, Chu Matsuda, Masayoshi Yasui, Hiroshi Miyata
Summary: This study compared postoperative recurrence patterns and outcomes in patients with radical esophagectomy after preoperative CRT or DCF. The results showed that DCF patients had fewer distant recurrences, while CRT patients had better control of locoregional recurrence but higher risk of distant recurrence.
Article
Oncology
Katsuhiko Nara, Takehito Yamamoto, Yasuyoshi Sato, Koichi Yagi, Koichiro Kawasaki, Tetsuro Toriumi, Tappei Takada, Yasuyuki Seto, Hiroshi Suzuki
Summary: This study investigated whether a low skeletal muscle mass index (SMI) is an independent risk factor for febrile neutropenia (FN) in patients with esophageal cancer receiving DCF therapy. The results showed that the incidence of FN was significantly higher in the low-SMI group, and low SMI was identified as an independent risk factor for FN.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Thomas Matoska, Anjishnu Banerjee, Aditya Shreenivas, Lauren Jurkowski, Monica E. Shukla, Elizabeth M. Gore, Paul Linsky, Mario Gasparri, Ben George, Candice Johnstone, David Johnstone, Lindsay L. Puckett
Summary: This study concludes that patients with oligometastatic esophageal cancer who were treated with definitive chemoradiotherapy had improved overall survival compared to those who received palliative treatment or historical controls.
Article
Oncology
Laure Herve, Stefano Kim, Jihane Boustani, Elodie Klajer, Mandy Pernot, Thierry Nguyen, Zaher Lakkis, Christophe Borg, Angelique Vienot
Summary: For patients with advanced rectal squamous cell carcinoma, induction mDCF chemotherapy followed by chemoradiotherapy is a safe and highly effective option, which should be considered for metastatic stage or locally advanced disease with an organ-preservation strategy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Cagatay Arslan, Fatos Dilan Atilla
Summary: The modified DCF (mDCF) regimen and capecitabine maintenance have shown high efficacy and longer time to progression (TTP) in the first-line treatment of metastatic gastric cancer (MGC).
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
J. De Vos-Geelen, S. M. E. Geurts, G. A. P. Nieuwenhuijzen, F. E. M. Voncken, J. A. Bogers, P. M. Braam, C. T. Muijs, M. A. de Jong, N. Kasperts, T. Rozema, G. J. Blom, S. A. W. Bouwense, L. B. J. Valkenburg-van Iersel, P. M. Jeene, F. J. P. Hoebers, V. C. G. Tjan-Heijnen
Summary: This retrospective study aimed to determine recurrence patterns and overall survival in patients with proximal esophageal cancer who achieved a clinical complete response after definitive chemoradiation therapy. Results showed that most recurrences were locoregional and occurred within the first three years post-treatment. This suggests the need to shorten locoregional follow-up from five to three years.
Article
Oncology
Hu Qiu, Haixia Song, Man Luo, Shaobo Ke, Wei Shi, Jiamei Chen, Wensi Zhao, Hesheng Luo, Yongshun Chen
Summary: This study found that dysfunction of apoptosis and autophagy correlated with early local recurrence in patients with locally advanced ESCC receiving dCRT. Abnormal expression levels of certain apoptosis-related genes in recurrent tumors were associated with increased risk of early local recurrence. Further studies are necessary to understand the biology of tumor recurrence in esophageal cancer.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Ken Sasaki, Yusuke Tsuruda, Masataka Shimonosono, Masahiro Noda, Yasuto Uchikado, Takaaki Arigami, Daisuke Matsushita, Shinichiro Mori, Akihiro Nakajo, Hiroshi Kurahara, Takao Ohtsuka
Summary: This study compared the efficacy of cisplatin and 5-fluorouracil (CF) with docetaxel and CF (DCF) in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC). While both groups had similar rates of pathological complete response, the DCF group showed significantly better 5-year disease-free survival and 5-year overall survival compared to the CF group.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Kotaro Yamashita, Shinya Urakawa, Tomo Ishida, Osamu Shiraishi, Keijiro Sugimura, Hiroshi Miyata, Masaaki Motoori, Kazumasa Fujitani, Atsushi Takeno, Motohiro Hirao, Yutaka Kimura, Taroh Satoh, Masahiko Yano, Hidetoshi Eguchi, Yuichiro Doki, Takushi Yasuda
Summary: The study compared the efficacy of two versus three cycles of neoadjuvant chemotherapy for treating locally advanced esophageal squamous cell carcinoma and found no significant differences in terms of R0 resection rates, pN0 rates, and 2-year progression-free survival rates. Only patients aged under 65 years old showed a tendency for better survival with the three-course treatment.
BRITISH JOURNAL OF CANCER
(2022)